IP Library Granted Patent US 7,662,866
Granted Patent B2
US 7,662,866 · App. 10/517,226 · Granted Feb 16, 2010

Polymeric support having novel pore structures

Assignee: GE Healthcare Bio-Sciences AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,866
App. No.
10/517,226
Granted
Feb 16, 2010
Kind
B2
Abstract

The invention is a method of producing a cross-linked polymeric support having a multimodal pore structure, which comprises providing a degradable initiator molecule; providing an organic phase comprising said initiator molecule, radically polymerizable monomers and a porogen in a solvent; providing an aqueous phase comprising a transition metal catalyst; suspension polymerization of the organic phase by adding a ligand, co-ordinating to the transition metal in the aqueous phase to produce a cross-linked polymeric support having a primary pore structure and comprising initiator molecule; and subjecting the support obtained to degrading conditions to remove the initiator molecule from within the support to produce a cross-linked polymeric support having a secondary pore structure in addition to the primary pore structure.

Claims (24)

1. A method of producing a cross-linked polymeric support having a multimodal pore structure, comprising the steps of:

(a) providing a degradable initiator molecule;

(b) providing an organic phase, which comprises said initiator molecule, one or more radically polymerisable monomers and a porogen in a solvent, and an aqueous phase, which comprises a transition metal catalyst;

(c) forming a suspension of the organic phase and the aqueous phase;

(d) starting a suspension polymerisation of the organic phase in the aqueous phase by adding a ligand, which co-ordinates to the transition metal in the aqueous phase via at least one atom, to produce a cross-linked polymeric support having a primary pore structure and comprising initiator molecule; and

(e) subjecting the support obtained from step (d) to degrading conditions to at least partially remove the initiator molecule from within the support to produce a cross-linked polymeric support having a secondary pore structure in addition to the primary pore structure.

2. The method of claim 1 , wherein the initiator molecule is a macroinitiator.

3. The method of claim 1 , wherein step (a) comprises to react a compound that comprises at least one hydroxy group, primary amine group or secondary amine group with an alfa-haloacyl halide.

4. The method of claim 3 , wherein a hydroxy-functional dendritic polyester is reacted with the alfa-haloacyl halide.

5. The method of claim 3 , wherein an amino-functional dendritic polyamide is reacted with the alfa-haloacyl halide.

6. The method of claim 1 , wherein in step (d), the organic phase comprises up to about 50% of the initiator molecule, calculated as weight/weight monomer.

7. The method of claim 1 , wherein the monomers are synthetic mono and/or multifunctional monomers, such as styrene and/or divinyl benzene.

8. The method of claim 1 , wherein the transition metal is selected from the group consisting of Cu, Ni, Pd, Ru and Fe.

9. The method of claim 1 , wherein the ligand comprises one or more N, O, P, S or C atoms that co-ordinated to the transition metal to form a catalyst system.

10. The method of claim 1 , wherein the removal according to step (e) is performed under basic or acidic conditions.

11. The method of claim 1 , wherein the removal according to step (e) is performed by applying an external agent.

12. The method of claim 1 , wherein a cross-linked polymeric support is produced comprising one functionality within a primary pore structure and one functionality within a secondary pore structure and an additional step of selective surface modification of the supports so obtained after step (d) but before step (e).

13. The method of claim 12 , wherein the surface of the support obtained from step (d) is modified using conditions that have no essential impact on the initiator molecule present in the support.

14. The method of claim 1 , wherein the secondary pore size is controlled by the molecular weight of the initiator molecule.

15. The method of claim 1 , wherein a cross-linked porous polymeric support has been produced.

16. The polymeric support of claim 15 , comprising one or more essentially spherical particles having a diameter of about 10 μm and 250 μm, wherein the specific surface area is in a range of 150-300 m 2 /g.

17. The polymeric support of claim 15 , which is a monolith.

18. The polymeric support of claim 15 , comprising functional groups, such as chromatography ligands, coupled to the surface of the primary pores and/or the secondary pores.

19. The use of the polymeric support of claim 15 as a matrix in chromatography.

Assignments (2)
CHANGE OF NAME Recorded Feb 21, 2006
From: PHARMACIA FINE CHEMICALS AB; PHARMACIA LKB BIOTECHNOLOGY AB; PHARMACIA BIOTECH AB; APBIOTECH AB; AMERSHAM PHARMACIA BIOTECH AB; AMERSHAM BIOSCIENCES AB
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 017186/0644 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2004
From: BUSSON, PHILIPPE; PALMGREN, RONNIE; MORRISON, MICHAEL
To: AMERSHAM BIOSCIENCES AB
Reel/Frame 015480/0019 →
Priority Claims (1)
SE 0202016 · Jun 27, 2002 · national
Continuity (1)
Related Publication 20050245624A1 · Nov 3, 2005